Impact of protein and small molecule interactions on kinase conformations.

biochemistry cell-based reporter assay chemical biology dark kinome drug interactions enzyme reactivation hard-to-target enzymes kinase complex formation kinase conformation kinase scaffolding function none pseudo enzymes target engagement

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
01 Aug 2024
Historique:
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: epublish

Résumé

Protein kinases act as central molecular switches in the control of cellular functions. Alterations in the regulation and function of protein kinases may provoke diseases including cancer. In this study we investigate the conformational states of such disease-associated kinases using the high sensitivity of the kinase conformation (KinCon) reporter system. We first track BRAF kinase activity conformational changes upon melanoma drug binding. Second, we also use the KinCon reporter technology to examine the impact of regulatory protein interactions on LKB1 kinase tumor suppressor functions. Third, we explore the conformational dynamics of RIP kinases in response to TNF pathway activation and small molecule interactions. Finally, we show that CDK4/6 interactions with regulatory proteins alter conformations which remain unaffected in the presence of clinically applied inhibitors. Apart from its predictive value, the KinCon technology helps to identify cellular factors that impact drug efficacies. The understanding of the structural dynamics of full-length protein kinases when interacting with small molecule inhibitors or regulatory proteins is crucial for designing more effective therapeutic strategies.

Identifiants

pubmed: 39088265
doi: 10.7554/eLife.94755
pii: 94755
doi:
pii:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1
BRAF protein, human EC 2.7.11.1
Protein Kinase Inhibitors 0
Protein Serine-Threonine Kinases EC 2.7.11.1
Protein Kinases EC 2.7.-
AMP-Activated Protein Kinase Kinases EC 2.7.11.3
STK11 protein, human EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Universität Innsbruck
ID : WS104004
Organisme : Universität Innsbruck
ID : WS104005
Organisme : Horizon 2020 Framework Programme
ID : cONCReTE (872391)
Organisme : Austrian Science Fund
ID : 10.55776/P30441
Organisme : Austrian Science Fund
ID : 10.55776/P32960
Organisme : Austrian Science Fund
ID : 10.55776/P35159
Organisme : Austrian Science Fund
ID : 10.55776/I5406
Organisme : Österreichische Forschungsförderungsgesellschaft
ID : 877163

Informations de copyright

© 2024, Kugler, Schwaighofer et al.

Déclaration de conflit d'intérêts

VK, SS, AF, FE, JF, SS, SS, RW, JT, VS, PM, TK No competing interests declared, PT, ES ES and PT are co-founders of KinCon biolabs; KinCon-reporters are subject of patents (WO2018060415A1)

Auteurs

Valentina Kugler (V)

Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.

Selina Schwaighofer (S)

Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.

Andreas Feichtner (A)

Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.

Florian Enzler (F)

Daniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Jakob Fleischmann (J)

Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.

Sophie Strich (S)

Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.

Sarah Schwarz (S)

Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.

Rebecca Wilson (R)

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.

Philipp Tschaikner (P)

Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.
KinCon biolabs GmbH, Innsbruck, Austria.

Jakob Troppmair (J)

Daniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Veronika Sexl (V)

University of Innsbruck, Innsbruck, Austria.

Pascal Meier (P)

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.

Teresa Kaserer (T)

Institute of Pharmacy/Pharmaceutical Chemistry and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.

Eduard Stefan (E)

Institute for Molecular Biology and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innsbruck, Austria.
Tyrolean Cancer Research Institute (TKFI), Innsbruck, Austria.
KinCon biolabs GmbH, Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH